Edition:
United Kingdom

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

2.39USD
4:22pm GMT
Change (% chg)

$-0.14 (-5.53%)
Prev Close
$2.53
Open
$2.53
Day's High
$2.62
Day's Low
$2.36
Volume
15,071
Avg. Vol
107,001
52-wk High
$51.00
52-wk Low
$2.36

Latest Key Developments (Source: Significant Developments)

Iroquois Capital Management Reports 9.99 Pct Passive Stake In Tonix Pharmaceuticals Holding
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Tonix Pharmaceuticals Holding Corp ::IROQUOIS CAPITAL MANAGEMENT LLC REPORTS 9.99 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING CORP AS OF DECEMBER 7 - SEC FILING.  Full Article

Tonix Pharmaceuticals Files For Offering Of Up To 4.3 Mln Shares
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS HOLDING CORP FILES FOR OFFERING OF UP TO 4.3 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Tonix Pharma Presents Results Of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies Of Tonmya®
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS PRESENTS RESULTS AND RETROSPECTIVE ANALYSES OF TWO DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED 12-WEEK STUDIES OF TONMYA® IN MILITARY-RELATED PTSD AT THE 2018 MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM.  Full Article

Tonix Pharmaceuticals Receives Fast Track Designation From FDA For TNX-102 SL
Monday, 16 Jul 2018 

July 16 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FROM THE U.S. FDA FOR TNX-102 SL FOR TREATMENT OF AGITATION IN ALZHEIMER’S DISEASE.TONIX PHARMACEUTICALS- TNX-102 SL IS CURRENTLY IN A PHASE 3 STUDY FOR MILITARY-RELATED PTSD, WITH AN INTERIM ANALYSIS EXPECTED IN Q3 OF 2018.  Full Article

Tonix Pharmaceuticals Holding Corp Enters Into Sales Agreement With Cowen And Co
Thursday, 17 May 2018 

May 17 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS HOLDING CORP SAYS ON MAY 1, CO ENTERED INTO SALES AGREEMENT WITH COWEN AND CO RELATING TO SHARES OF CO'S COMMON STOCK OFFERED.TONIX PHARMACEUTICALS HOLDING SAYS CO MAY OFFER, SELL SHARES OF CO'S COMMON STOCK OF UP TO $9.5 MILLION THROUGH COWEN - SEC FILING.  Full Article

Tonix Pharmaceuticals Holding Qtrly Net Loss Per Common Share $0.88
Friday, 11 May 2018 

May 11 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS HOLDING CORP QTRLY NET LOSS PER COMMON SHARE $0.88.  Full Article

Tonix Pharma Reports Q4 Loss Per Share $0.71
Monday, 12 Mar 2018 

March 12 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE.Q4 LOSS PER SHARE $0.71.  Full Article

Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Tonix Pharmaceuticals Holding Corp ::TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE.PLAN TO SUBMIT TNX-102 SL IND FOR AGITATION IN ALZHEIMER'S DISEASE IN Q1 OF 2018.  Full Article

Tonix Pharmaceuticals Q3 loss per share $0.77
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Tonix Pharmaceuticals Holding Corp :Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update.Q3 loss per share $0.77.Tonix Pharmaceuticals Holding Corp - ‍at September 30, 2017, Tonix had cash and cash equivalents of $29.3 million​.  Full Article

Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Tonix Pharmaceuticals Holding Corp :Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD.Tonix Pharmaceuticals Holding Corp - ‍proposed CMC data package to support Tonmya's NDA and commercial manufacturing plans was accepted by FDA​.Tonix Pharmaceuticals Holding - ‍FDA official minutes reflect co's readiness to manufacture Tonmya commercial product at production scale​.Tonix Pharmaceuticals Holding - ‍Tonmya has been conditionally accepted by FDA as proposed trade name for TNX-102 SL (cyclobenzaprine hcl sublingual tablets) for PTSD​.  Full Article